Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash & Current Investments (2016 - 2025)

Vanda Pharmaceuticals' Cash & Current Investments history spans 16 years, with the latest figure at $263.8 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 29.57% year-over-year to $263.8 million; the TTM value through Dec 2025 reached $263.8 million, down 29.57%, while the annual FY2025 figure was $263.8 million, 29.57% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $263.8 million at Vanda Pharmaceuticals, up from $223.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $501.5 million in Q1 2023 and bottomed at $223.7 million in Q3 2025.
  • The 5-year median for Cash & Current Investments is $395.3 million (2021), against an average of $388.7 million.
  • The largest annual shift saw Cash & Current Investments grew 21.08% in 2021 before it tumbled 41.87% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $432.8 million in 2021, then grew by 7.87% to $466.9 million in 2022, then dropped by 16.83% to $388.3 million in 2023, then decreased by 3.51% to $374.6 million in 2024, then fell by 29.57% to $263.8 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Cash & Current Investments are $263.8 million (Q4 2025), $223.7 million (Q3 2025), and $244.6 million (Q2 2025).